



GSK Multi-Vaccine Infant Study

Criteria: Healthy infants aged 8-12 weeks at the time of first vaccination.

Study Goal: To study a new combination vaccine that combines MenC vaccination with other vaccines that are now routinely administered to babies in the vast majority of countries in Europe and North America. The new study vaccine being studied may, therefore, protect against Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type B, and Group C Meningococcal (MenC) invasive diseases.

Participation requirements: Physical exam, administration of vaccines, blood sampling, and diary card record.

Contact: Clinical Research Unit at 789-3206.